Page 19 - IJB-6-3

Kirillova, et al.
14. Afsana, Jain V, Haider N, et al. 2019, 3D Printing in 30. Gulyaev VA, Khubutiya MS, Novruzbekov MS, et al., 2019,
Personalized Drug Delivery. Curr Pharm Des, 24:5062– Xenotransplantation: History, Problems and Development
5071. DOI: 10.2174/1381612825666190215122208. Prospects. Transplantol Russ J Transplant, 11:37–54.
15. Amorim CA, 2011, Artificial ovary. In: Practice of Fertility 31. Blum B, Benvenisty N, 2009, The Tumorigenicity of Diploid
Preservation. Cambridge University Press, Cambridge, pp. and Aneuploid Human Pluripotent Stem Cells. Cell Cycle,
448–458. 8:3822–3830. DOI: 10.4161/cc.8.23.10067.
16. Amorim CA, Shikanov A, 2016, The Artificial Ovary: Current 32. Nori S, Okada Y, Nishimura S, et al., 2015, Long-Term
Status and Future Perspectives. Future Oncol, 12:2323–2332. Safety Issues of iPSC-Based Cell Therapy in a Spinal Cord
DOI: 10.2217/fon-2016-0202. Injury Model: Oncogenic Transformation with Epithelial-
17. Krotz SP, Robins JC, Ferruccio TM, et al., 2010, In Vitro Mesenchymal Transition. Stem Cell Rep, 4:360–373.
Maturation of Oocytes Via the Pre-fabricated Self-assembled DOI: 10.1016/j.stemcr.2015.01.006.
Artificial Human Ovary. J Assist Reprod Gen, 27:743–750. 33. Tang W, 2019, Challenges and Advances in Stem Cell
DOI: 10.1007/s10815-010-9468-6. Therapy. BioScience Trends, 13:286–286.
18. Cho E, Kim YY, Noh K, et al., 2019, A New Possibility in 34. Andrews PW, Ben-David U, Benvenisty N, et al., 2017,
Fertility Preservation: The Artificial Ovary. J Tissue Eng Assessing the Safety of Human Pluripotent Stem Cells and
Regen Med, 13:1294–1315. DOI: 10.1002/term.2870. Their Derivatives for Clinical Applications. Stem Cell Rep,
19. Yudin BG, 2016, Institutionalization of Bioethics and Human 9:1–4. DOI: 10.1016/j.stemcr.2017.05.029.
Enhancement. Workbooks Bioeth, 23:5–11. 35. Sullivan S, Stacey GN, Akazawa C, et al., 2018, Quality
20. Tishchenko PD, 2015, Designing of the Person: Ideals and Control Guidelines for Clinical-grade Human Induced
Technologies. Workbooks Bioeth, 24:36–64. Pluripotent Stem Cell Lines. Regen Med, 13:859–866.
21. Bushev S, 2018, The Philosophical and Natural-science 36. Jo HY, Han HW, Jung I, et al., 2020, Development of Genetic
Aspects of the Study of the Problem of Aging and Quality Tests for Good Manufacturing Practice-compliant
Technological Immortality. Soc Poli Nauki, 3:198-200. Induced Pluripotent Stem Cells and their Derivatives. Sci
22. Yudin GA, 2019, Communitarian Approach for Bioethics, Rep, 10(1):3939. DOI: 10.1038/s41598-020-60466-9.
Ethical Thought, 19(1):36-48. 37. The Presidential Commission for the Study of Bioethical
23. Yudin B, 2016, Technoscience and “Human Enhancement”. Issues, 2016, Privacy and Progress in whole Genome
Epistemol Philos Sci, 48(2):18-27. Sequencing. Available from: https://www.bioethicsarchive.
24. Gilbert F, O’Connell CD, Mladenovska T, et al., 2018, Print georgetown.edu/pcsbi/sites/default/files/6%20Privacy%20
Me an Organ? Ethical and Regulatory Issues Emerging from -%20Privacy%20and%20Progress%209.30.16.pdf..
3D Bioprinting in Medicine. Sci Eng Ethics, 24(1):73–91. 38. Vasiliev SA, Osavelyuk AM, Burtcev AK, et al., 2019,
DOI: 10.1007/s11948-017-9874-6. Problems of Legal Regulation of Diagnostics and Human
25. Gilbert F, Viaña JNM, O’Connell CD, et al., 2018, Enthusiastic Genome Editing in the Russian Federation. Lex Russica,
Portrayal of 3D Bioprinting in the Media: Ethical Side Effects. 6:71–79. DOI: 10.17803/1729-5920.2019.151.6.071-079.
Bioethics, 32(2):94–102. DOI: 10.1111/bioe.12414. 39. Stambolsky DV, Bryzgalina EV, Efimenko AY, et al., 2018,
26. Directive 2004/23/EC of the European parliament and of the Informed Consent to the Receipt and use of Human Cellular
council of 31 March 2004 on setting standards of quality and Material: Juristic and Ethical Regulation. Russ J Cardiol,
safety for the donation, procurement, testing, processing, 12:84–90. DOI: 10.15829/1560-4071-2018-12-84-91.
preservation, storage and distribution of human tissues and 40. Osborn LS, 2014, Regulating Three-Dimensional Printing:
cells 2004. Off J Eur Union, 102:48–58. The Converging Worlds of Bits and Atoms. Vol. 51. Campbell
27. Russian Federation. Federal Law dated 23.06.2016 No. 180- University School of Law, San Diego Law Review, pp.
FZ “on Biomedical Cellular Products”. Russian Federation, 553-622.
Moscow. 41. Bogdanov DE, 2019, Bioprinting Technology as a
28. Lo B, Parham L, 2009, Ethical Issues in Stem Cell Research. Legal Challenge: Determining the Model of Legal
Endocr Rev, 30:204–213. Regulation. Lex Russica, 6:80-91. DOI: 10.17803/1729-
29. Volarevic V, Markovic BS, Gazdic M, et al., 2018, Ethical 5920.2019.151.6.080-091.
and Safety Issues of Stem Cell-Based Therapy. Int J Med Sci, 42. Degtyarev YG, Fomin OY, Soltanovich AV, et al., 2014,
15:36–45. DOI: 10.7150/ijms.21666. Informed Consent for Medical Interference: Medical and

International Journal of Bioprinting (2020)–Volume 6, Issue 3 15